Stocks Health care GRCE
NASDAQ · Health careGrace Therapeutics, Inc. (GRCE)
It posted a net loss of $20.2M. At June 30, 2026 it held $13.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Grace Therapeutics, Inc.
- Net worth
- Grace Therapeutics, Inc. has a market value (market cap) of $39.1M at the latest share price, and shareholders' equity of $48.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $100M (+50,920.4% year on year), with a net loss of $9.8M.
- Cash flow
- In fiscal 2026 operations used $8.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Grace Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Grace Therapeutics, Inc. does
Grace Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GRCE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | n/a | -$7.8M | -$0.47 | n/a |
| 2025 | n/a | -$9.6M | -$0.79 | n/a |
| 2024 | n/a | -$12.9M | -$1.35 | n/a |
| 2023 | n/a | -$42.4M | -$5.71 | n/a |
| 2022 | $100M | -$9.8M | -$1.62 | n/a |
| 2021 | $196K | -$19.7M | -$7.99 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Grace Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 18, 2026
- August 24, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 13, 2026
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- August 6, 2026
- July 28, 2026Additional proxy material DEFA14A
- July 28, 2026Proxy statement DEF 14A
Insider trades
What the people running Grace Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $442K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Opaleye Management Inc.10% owner | Boughtindirect | 1,694 | $3.5K |
| October 2, 2026 | Opaleye Management Inc.10% owner | Boughtindirect | 20,000 | $41.4K |
| October 1, 2026 | Opaleye Management Inc.10% owner | Boughtindirect | 38,796 | $79K |
| September 29, 2026 | Opaleye Management Inc.10% owner | Boughtindirect | 7,849 | $16.4K |
| September 23, 2026 | Opaleye Management Inc.10% owner | Boughtindirect | 5,318 | $11.2K |
| September 21, 2026 | Opaleye Management Inc.10% owner | Boughtindirect | 9,771 | $20.5K |
| September 9, 2026 | Kohli PrashantChief Executive Officer, Director | Bought | 100,000 | $214K |
| September 9, 2026 | Opaleye Management Inc.10% owner | Boughtindirect | 5,836 | $12.2K |
Who owns GRCE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Opaleye Management Inc.13G, passive with 2 related filers | 13.07% | August 7, 2026 |
| ADAR1 Capital Management GP, LLC13G, passive with 2 related filers | 9.99% | November 14, 2024 |
| ADAR1 Capital Management, LLC13G, passive with 2 related filers | 9.9% | August 14, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 6.75% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 33 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Cerity Partners LLC | 849,055 | 0 |
| Eversept Partners, LP | 772,900 | +16,300 |
| Bank of America Corp | 494,698 | -25 |
| Vanguard Capital Management LLC | 411,714 | +10,058 |
| Citadel Advisors LLC | 349,740 | +250,998 |
| Cantor Fitzgerald, L. P. | 200,000 | new |
| Maven Securities LTD | 200,000 | new |
| Birchview Capital, LP | 120,000 | +70,000 |
| Two Sigma Investments, LP | 96,890 | new |
| Jane Street Group, LLC | 89,442 | -77,655 |
| XTX Topco Ltd | 71,668 | +8,574 |
| Susquehanna International Group, Llp | 49,577 | new |
| BlackRock, Inc. | 37,535 | new |
| Rangeley Capital, LLC | 26,000 | new |
| Kestra Private Wealth Services, LLC | 23,000 | +10,000 |
| UBS Group AG | 16,777 | -9,524 |
| Stratos Investment Management, LLC | 11,158 | new |
| Bnp Paribas Financial Markets | 10,500 | +3,400 |
| Scientech Research LLC | 10,184 | new |
| Oppenheimer & Co Inc | 10,000 | 0 |
Insiders
2 insiders reported holding 2,980,014 shares in total, about $5.5M at the last price.
| Holder | Shares |
|---|---|
| Opaleye Management Inc.10% owner | 2,858,6572,858,657 held indirectly |
| Kohli PrashantChief Executive Officer, Director | 121,357 |
Questions about GRCE
What does Grace Therapeutics, Inc. do?
Grace Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as GRCE. Its shares trade on NASDAQ under the ticker GRCE.
What is Grace Therapeutics, Inc.'s net worth?
Grace Therapeutics, Inc. has a market value (market cap) of $39.1M at the latest share price, and shareholders' equity of $48.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Grace Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $20.2M.
When did Grace Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from October 5, 2026.
When is Grace Therapeutics, Inc.'s next earnings report?
Grace Therapeutics, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare GRCE with
Follow GRCE
Get an email when Grace Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Grace Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.